Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Development and validation of a deep learning model to assess tumor progression to immunotherapy.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20601

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20601)

Author(s): Yi Yang, Jiancheng Yang, Yuxiang Ye, Tian Xia, Shun Lu; Shanghai Chest Hospital, Shanghai, China; Department of Electronic Engineering, Shanghai Jiao Tong University/Diannei Technology/Diannei Technology, Shanghai, China; Shanghai Diannei Technology, Shanghai, China; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China

Abstract Disclosures

Abstract:

Background: Manual application of length-based tumor response criteria is the standard-of-care for assessing metastatic tumor response. It is technically challenging, time-consuming and associated with low reproducibility. In this study, we presented a novel automatic Deep Neural Networks (DNNs) based segmentation method for assessing tumor progression to immunotherapy. Next stage, AI will assist Physicians assessing pseudo-progression. Methods: A data set of 39 lung cancer patients with 156 computed tomography (CT) scans was used for model training and validation. A 3D segmentation DNN DenseSharp, was trained with an input size of on CT scans of tumor with manual delineated volume of interest (VOI) as ground truth. The trained model was subsequently used to estimate the volumes of target lesions via 16 sliding windows. We referred the progression-free survival (PFS) only considering tumor size as PFS-T. PFS-Ts assessed by longest tumor diameter (PFS-Tdiam), by tumor volume (PFS-Tvol), and by predicted tumor volume (PFS-Tpred-vol) were compared with standard PFS (as assessed by one junior and one senior clinician). Tumor progression was defined as > 20% increase in the longest tumor diameter or > 50% increase in tumor volume. Effective treatment was defined as a PFS of > 60 days after immunotherapy. Results: In a 4-fold cross-validation test, the DenseSharp segmentation neural network achieved a mean per-class intersection over union (mIoU) of 80.1%. The effectiveness rates of immunotherapy assessed using PFS-Tdiam (32 / 39, 82.1%), PFS-Tvol (33/39, 84.6%) and PFS-T pred-vol (32/39, 82.1%) were the same as standard PFS. The agreement between PFS-Tvol, and PFS-Tpred-vol was 97.4% (38/39). Evaluation time with deep learning model implemented with PyTorch 0.4.1 on GTX 1080 GPU was hundred-fold faster than manual evaluation (1.42s vs. 5-10 min per patient). Conclusions: In this study, DNN based model demonstrated fast and stable performance for tumor progression evaluation. Automatic volumetric measurement of tumor lesion enabled by deep learning provides the potential for a more efficient, objective and sensitive measurement than linear measurement by clinicians.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...